Skip to main content
The Western Journal of Medicine logoLink to The Western Journal of Medicine
. 1993 May;158(5):536–537.

Future directions in sickle cell disease.

A Anand
PMCID: PMC1022151  PMID: 8342283

Full text

PDF
536

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benjamin L. J., Berkowitz L. R., Orringer E., Mankad V. N., Prasad A. S., Lewkow L. M., Chillar R. K., Peterson C. M. A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis. Blood. 1986 May;67(5):1442–1447. [PubMed] [Google Scholar]
  2. Berkowitz L. R., Orringer E. P. Effects of cetiedil on monovalent cation permeability in the erythrocyte: an explanation for the efficacy of cetiedil in the treatment of sickle cell anemia. Blood Cells. 1982;8(2):283–288. [PubMed] [Google Scholar]
  3. Rodgers G. P., Roy M. S., Noguchi C. T., Schechter A. N. Is there a role for selective vasodilation in the management of sickle cell disease? Blood. 1988 Mar;71(3):597–602. [PubMed] [Google Scholar]
  4. Stamatoyannopoulos J. A. Future prospects for treatment of hemoglobinopathies. West J Med. 1992 Dec;157(6):631–636. [PMC free article] [PubMed] [Google Scholar]
  5. Teuscher T., Von Der Ahe C. W., Baillod P., Holzer B. Double-blind randomised clinical trial of pentoxiphyllin in vaso-occlusive sickle cell crisis. Trop Geogr Med. 1989 Oct;41(4):320–325. [PubMed] [Google Scholar]

Articles from Western Journal of Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES